Abstract
Autoimmune pancreatitis (AIP) is a pancreatic phenotype of IgG4-related systemic disease. Since its first description in the literature, characteristic imaging features have gradually become known to many clinicians encompassing various specialties in the past quarter century. CT and MRI have been the workhorses for imaging diagnosis of AIP. Typical features include sausage-like swelling of the focal or entire pancreas, duct-penetrating sign, a capsule-like rim of the affected lesions, and homogeneous delayed enhancement or enhanced duct sign after contrast administration, as well as characteristic combined findings reflecting coexisting pathologies in the other organs as a systemic disease. In this review, recent and future developments in CT and MRI that may help diagnose AIP are discussed, including restricted diffusion and perfusion and increased elasticity measured using MR.

Keywords
IgG4 · Autoimmune pancreatitis · Computed tomography · Diffusion-weighted image · MR elastography

Introduction
Autoimmune pancreatitis (AIP) was first reported by Yoshida et al. [1] in 1995 as a disease that presents diffuse pancreatic swelling and tapered pancreatic ductal stenosis, ameliorated by steroid administration. Since then, AIP has been understood as a part of systemic IgG4-related diseases. The diagnostic criteria for AIP include the International Consensus Diagnostic Criteria (ICDC) [2] internationally, and the Japanese Clinical Diagnostic Criteria [3] in Japan. In these diagnostic criteria, pancreatic swelling (diffuse or segmental/focal) and irregular stenosis of the main pancreatic duct are described as items for diagnostic imaging. As data from more cases have become available, characteristic imaging findings on various modalities are gradually becoming known to many clinicians encompassing various specialties. In this article, representative findings of AIP on computed tomography (CT) and magnetic resonance imaging (MRI), which are considered the most versatile, and the results of recent research and their future potential, are shared.

CT and MRI findings of AIP
Contrast-enhanced CT has been the workhorse in the diagnosis of AIP. The iodinated contrast medium used for CT is a non-specific extravascular contrast medium and thereby is distributed into the fibrosis induced by AIP. The gadolinium chelate for MRI behaves similarly to the iodinated contrast medium, enhancing the fibrotic component of the tissues affected by AIP. MRI is also a powerful tool in AIP diagnosis because of its inherent tissue-characteristic contrasts. For instance, normal pancreatic tissue is depicted by a clear high signal on fat-saturated T1-weighted images; however, the high signals are lost in the area affected by AIP. Similarly, fibrosis is characterized by low intensity on T2-weighted images; therefore, the capsule-like rim demarcates the swollen pancreas with a low signal. In addition, a high signal on the diffusion-weighted image represents highly cellular plasmacyte...
proliferations. In addition, MRI can add physical properties such as tissue stiffness or rigidity into imaging contrast. Highly fibrotic tissues are associated with tissue stiffness; therefore, MRI can depict fibrotic AIP lesions on MR elastography [4].

**Pancreatic enlargement (diffuse or localized)**

The findings of AIP are created by significant lymphocytes or plasma cell infiltration and fibrosis. The appearance is often compared to sausage because the typical lobular structure disappears, and the margin of the pancreas becomes straight (Fig. 1a, b). The definition of pancreatic swelling has classically been dependent on the criteria proposed by Haaga et al. [5]. Still, in reality, it is better to consider the age and background of the patient comprehensively. Since the pancreas decreases in volume with age, a disproportionately large pancreas in an older patient suggests an abnormality. In such instances, it is strongly recommended to refer to previous images (Fig. 2a–c).

**Homogeneously decreased enhancement in the arterial or pancreatic phase**

Unlike the liver with its dual blood supplies, the pancreas is perfused solely by arterial blood flow; therefore, the healthy pancreas is characterized by a steep and homogeneous rise of enhancement after intravenous contrast administration. The area affected by AIP shows reduced enhancement in the arterial or pancreatic phase of contrast-enhanced dynamic CT (Fig. 1a).

**Homogeneous delayed enhancement**

In contrast to the reduced enhancement in the pancreatic phase, the affected area shows increased enhancement in the delayed phase compared to the normal pancreatic parenchyma (Fig. 1b). The contrast enhancement in the delayed phase is uniform [6], reflecting acinar cell shedding and a high degree of fibrosis. Homogeneous delayed enhancement

---

**Fig. 1** A male patient in his 70s with typical autoimmune pancreatitis (AIP). a There is localized sausage-like swelling of the pancreas affected by AIP (large arrows). These lesions are hypodense during the pancreatic phase as compared to the normal pancreas (small arrow). Typical rim enhancement (arrowheads) demarcating the pancreatic tail is seen. b The same coronal section on delayed-phase CT reveals the lesion is hyperdense during the delayed phase compared to the normal pancreatic parenchyma (small arrow). The rim is also discernible in the delayed phase (arrowheads).

**Fig. 2** A male patient in his 70s with autoimmune pancreatitis (AIP). a Seven years before the onset of AIP, there was no pancreatic swelling on contrast-enhanced CT (CECT). b At the onset of AIP, there is distinct sausage-like swelling of the pancreatic body to tail on CECT. The area affected by AIP is a homogeneously less enhanced area (large arrow) as compared to the unaffected area (small arrow). c One year after initiation of prednisolone, the affected lesion returned to a normal size and enhancement on CECT (arrow)
is a useful finding for differentiation of AIP from pancreatic ductal adenocarcinoma (PDAC) because its sensitivity, specificity, and accuracy are reported to be 59–100%, 65–94.9%, and 68.3–94.3%, respectively [6–13].

**Punctate enhancements in the pancreatic phase within the lesion**

The normal pancreatic parenchyma may focally remain within the diffusely affected AIP lesions. Such areas may still hold inherent arterial blood perfusion and thereby be depicted as punctate, speckled, or dotted contrast enhancements [7] (Fig. 3a, b). Punctate enhancements in the pancreatic phase within the lesion are useful findings for differentiation of AIP from PDAC, with its sensitivity, specificity, and accuracy reported to be 50–88.9%, 48.6–95%, and 62–91.7%, respectively [7, 10, 13].

**Enhanced duct sign**

In AIP, a contrast-enhanced area along the MPD wall may be seen [10, 14, 15] (Fig. 4a), which is thought to reflect the inflammations around the pancreatic duct. Furuhashi et al. [10] reported that the enhanced duct sign was a useful finding for differentiation of AIP from PDAC, with a sensitivity, specificity, and accuracy of 36%, 98%, and 82%, respectively.

**Capsule-like rim**

A band-like rim structure may be found in whole or in part demarcating the pancreas affected by AIP [14] (Figs. 1a, b, 3a, b). This finding is believed to reflect a high degree of fibrosis. CT shows an AIP-affected area as low density before contrast administration, whereas gradual contrast enhancement follows in the dynamic study. MRI shows a corresponding low signal rim on T2-weighted images reflecting these fibrotic areas (Fig. 5). Capsule-like rim is a useful finding for differentiation of AIP from PDAC because its sensitivity, specificity, and accuracy are reported to be 10–64%, 90.9–100%, and 70–93%, respectively [7–10, 12, 13, 16–18].

The contrast changes seen in AIP on MRI are more characteristic, if not specific, than on CT. On MRI fat-saturated...
T1-weighted images, normal pancreatic tissue is inherently characterized by a high signal; however, the integrities of the signal intensity and the texture of the pancreatic exocrine glands are lost in the affected lesion (Fig. 6a).

**Duct-penetrating sign**

In AIP, the main pancreatic duct (MPD) may penetrate the lesion without complete occlusion. In addition, the MPD stenosis in the lesion may taper, which is called the icicle sign [18]. Multiple skip narrowings of the MPD may also be seen (Fig. 6b) [17]. Magnetic resonance cholangiopancreatography (MRCP), its depiction not depending on luminal contrast delivery upstream to the stenosis, is suitable for depicting the entire MPD pathologies affected by AIP. Therefore, MRCP can readily display the icicle sign in the multiple skipped segments. The duct-penetrating sign is a useful finding for differentiation of AIP from PDAC, with its sensitivity, specificity, and accuracy reported to be 13.3–73%, 91.4–100%, and 68–93%, respectively [7, 8, 10, 11, 13, 17, 18].

**Imaging findings of AIP after steroid therapy**

In cases of AIP, steroid treatment improves pancreatic swelling [19, 20]. In some cases, the pancreatic parenchyma may be more atrophic than before treatment. The capsule-like rim disappears and the main pancreatic duct stenosis improves. In our experience, the enhanced duct sign also disappears, but the contrast enhancement of the pancreatic parenchyma may not be completely normalized. At the time of recurrence, these abnormal findings will reappear.

**Extrapancreatic lesions**

Typical extrapancreatic lesions of AIP include sclerosing cholangitis [21] (Fig. 4b), retroperitoneal fibrosis [22], and interstitial nephritis [23]. In sclerosing cholangitis, the bile duct wall is thickened, and the contrast enhancement is increased. Retroperitoneal fibrosis is often visualized on CT as a soft tissue density area surrounding the abdominal aorta or bilateral common iliac arteries. Lesions of interstitial nephritis are seen as areas of poor contrast enhancement and are visualized as low-intensity lesions on T2-weighted images. In addition, lacrimal gland or salivary gland inflammation [24], interstitial pneumonia [25], and lymphadenopathy [26] may be seen. These findings are not always present; however, it is a basis for suspicion of AIP if found.
Recent research

**Diffusion-weighted images (DWI)**

Due to plasma cell proliferation, the AIP lesion shows a high signal on diffusion-weighted images (DWI) (Fig. 7a). Ren et al. reported that the apparent diffusion coefficient (ADC) map helped distinguish mass-forming-type AIP from PDAC [27]. They found that the areas under the curve (AUCs) of receiver operating characteristic (ROC) were maximized when using the maximum ADC value as a parameter. Choi et al. reported that the mean ADC value of the lesion was significantly lower in mass-forming AIP than in PDAC [11]. The sensitivity and specificity were 66.7% and 81.0%, respectively, when the ADC values were separated by $0.9407 \times 10^{-3}$ mm$^2$/s (Fig. 7b). Zhu et al. investigated mean ADC values after treatment with AIP and recurrence [28]. According to them, the ADC value of AIP is increased by steroid treatment, but not so much at the time of recurrence. Therefore, they reported that the accuracy might decrease when predicting recurrence using the ADC value. Sekito et al. investigated the usefulness of ADC values in differentiating type 1 localized AIP from PDAC and further determining the therapeutic effect. They reported that the mean ADC values of the lesions were significantly lower in AIP than in PDAC and were elevated considerably after steroid treatment [29].

**Intravoxel incoherent motion (IVIM)**

Klauss et al. compared perfusion rates of AIP, PDAC, and the normal pancreas in terms of intravoxel incoherent motion (IVIM) [30]. They reported that the perfusion rate was significantly lower in AIP than in the normal pancreas, and in addition, the rate was the lowest in PDAC. Interestingly, the rate of AIP perfusion increased after steroid therapy.

**MR elastography (MRE)**

Shi et al. compared the rigidity of AIP with that of PDAC using MR elastography (MRE). They reported the rigidity or stiffness of PDAC and AIP [31] concluding the median value was significantly lower in AIP ($2.67$ kPa [interquartile range $2.24–3.56$ kPa]) than in PDAC ($3.78$ kPa [3.22–5.11 kPa]); however, in our experiences, the stiffness of AIP considerably varies depending on its pathological phases (Fig. 8a, b).

---

Fig. 7  A male patient in his 70.
**a** On diffusion-weighted image, a homogeneously hyperintense body to tail (arrow) suggests highly cellular plasmacyte proliferation seen in autoimmune pancreatitis. **b** On the ADC map, the ADC value of the lesion is $0.8 \times 10^{-3}$ mm$^2$/s

Fig. 8  A male in his 50 s with IgG4-related autoimmune pancreatitis (AIP) associated with pathologically proven desmoplastic inflammatory pseudotumor.
**a** Contrast-enhanced T1-weighted image showing delayed positive enhancement of the lesion in the pancreatic head (arrow).
**b** A color-coded stiffness map shows a high stiffness of $6.2$ kPa in the lesion (arrow), higher than previously reported values for AIP
Besides MRI, ultrasound elastography may be promising since similar information concerning the pancreas stiffness can be obtained with better spatial resolution than MRE [32–35].

Conclusions

Imaging diagnosis of AIP is not very difficult thanks to its characteristic findings. CT and MRI are the most standard methods for the diagnosis, and further cutting-edge research and developments are underway.

Declarations

Conflict of interest The second author, Yasuo Takehara, is an endowed chair of a department financially supported by a private company; however, the status is irrelevant to the contents of this paper. Other authors declare that there are no conflicts of interest related to the contents of the article.

Ethical approval All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients for being included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.
2. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–8.
3. Kawa S, Kamisawa T, Notohara K, et al. Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2018: revision of Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2011. Pancreas. 2020;49:e13–4.
4. Itoh Y, Takehara Y, Kawase T, et al. Feasibility of magnetic resonance elastography for the pancreas at 3T. J Magn Reson Imaging. 2016;43:384–90.
5. Haaga JR, Alfidi RJ, Zelch MG, et al. Computed tomography of the pancreas. Radiology. 1976;120:589–95.
6. Wakabayashi T, Kawaura Y, Satomura Y, et al. Clinical and imaging features of autoimmune pancreatitis with focal pancreatic swelling or mass formation: comparison with so-called tumor-forming pancreatitis and pancreatic carcinoma. Am J Gastroenterol. 2003;98:2679–87.
7. Sugiyama Y, Fujinaga Y, Kadoya M, et al. Characteristic magnetic resonance features of focal autoimmune pancreatitis useful for differentiation from pancreatic cancer. Jpn J Radiol. 2012;30:296–309.
8. Muhi A, Ichikawa T, Motosugi U, et al. Mass-forming autoimmune pancreatitis and pancreatic carcinoma: differential diagnosis on the basis of computed tomography and magnetic resonance cholangiopancreatography, and diffusion-weighted imaging findings. J Magn Reson Imaging. 2012;35:827–36.
9. Sun GF, Zuo CJ, Shao CW, et al. Focal autoimmune pancreatitis: radiological characteristics help to distinguish from pancreatic cancer. World J Gastroenterol. 2013;19:3634–41.
10. Furuhashi N, Suzuki K, Sakurai Y, et al. Differentiation of focal-type autoimmune pancreatitis from pancreatic carcinoma: assessment by multiphase contrast-enhanced CT. Eur Radiol. 2015;25:1366–74.
11. Cho SY, Kim SH, Kang TW, et al. Differentiating mass-forming autoimmune pancreatitis from pancreatic ductal adenocarcinoma on the basis of contrast-enhanced MRI and DWI findings. AJR Am J Roentgenol. 2016;206:291–300.
12. Lee S, Kim JH, Kim SY, et al. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Eur Radiol. 2018;28:5267–74.
13. Kwon JH, Kim JH, Kim SY, et al. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. Eur Radiol. 2019;29:5763–71.
14. Suzuki K, Itoh S, Nagasaka T, et al. CT findings in autoimmune pancreatitis: assessment using multiphase contrast-enhanced multissection CT. Clin Radiol. 2010;65:735–43.
15. Kawai Y, Suzuki K, Itoh S, et al. Autoimmune pancreatitis: assessment of the enhanced duct sign on multiphase contrast-enhanced computed tomography. Eur J Radiol. 2012;81:3055–60.
16. Takahashi N, Fletcher JG, Fidler JL, et al. Dual-phase CT of autoimmune pancreatitis: a multireader study. AJR Am J Roentgenol. 2008;190:280–6.
17. Hur BY, Lee JM, Lee JE, et al. Magnetic resonance imaging findings of the mass-forming type of autoimmune pancreatitis: comparison with pancreatic adenocarcinoma. J Magn Reson Imaging. 2012;36:188–97.
18. Kim HJ, Kim YK, Jeong WK, et al. Pancreatic duct “icicle sign” on MRI for distinguishing autoimmune pancreatitis from pancreatic ductal adenocarcinoma in the proximal pancreas. Eur Radiol. 2015;25:1551–60.
19. Matsubayashi H, Ishiwatari H, Imai K, et al. Steroid therapy and steroid response in autoimmune pancreatitis. Int J Mol Sci. 2019;21:257.
20. Manfredi R, Frulloni L, Mantovani W, et al. Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence. Radiology. 2011;260:428–36.
21. Nakazawa T, Ohara H, Yamada T, et al. Atypical primary sclerosing cholangitis cases associated with unusual pancreatitis. HEPATOGASTROENTEROLOGY. 2001;48:625–30.
22. Hamano H, Kawa S, Ochi Y, et al. Hydatidosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet. 2002;359:1403–4.
23. Uchiyama-Tanaka Y, Mori Y, Kimura T, et al. Acute tubulointerstitial nephritis associated with autoimmune-related pancreatitis. Am J Kidney Dis. 2004;43:e18-25.
24. Kamisawa T, Funata N, Hayashi Y, et al. Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis. Gut. 2003;52:683–7.
25. Hirano K, Kawabe T, Komatsu Y, et al. High-rate pulmonary involvement in autoimmune pancreatitis. Intern Med J. 2006;36:58–61.
26. Saegusa H, Momose M, Kawa S, et al. Hilar and pancreatic gallium-67 accumulation is characteristic feature of autoimmune pancreatitis. Pancreas. 2003;27:20–5.
27. Ren H, Mori N, Hamada S, et al. Effective apparent diffusion coefficient parameters for differentiation between mass-forming autoimmune pancreatitis and pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2021;46:1640–7.
28. Zhu L, Zhang W, Jin Z, et al. DWI of autoimmune pancreatitis: is it an imaging biomarker for disease activity? AJR Am J Roentgenol. 2021;216:1240–6.
29. Sekito T, Ishii Y, Serikawa M, et al. The role of apparent diffusion coefficient value in the diagnosis of localized type 1 autoimmune pancreatitis: differentiation from pancreatic ductal adenocarcinoma and evaluation of response to steroids. Abdom Radiol (NY). 2021;46:2014–24.
30. Klauss M, Maier-Hein K, Tjaden C, et al. IVIM DW-MRI of autoimmune pancreatitis: therapy monitoring and differentiation from pancreatic cancer. Eur Radiol. 2016;26:2099–106.
31. Shi Y, Cang L, Zhang X, et al. The use of magnetic resonance elastography in differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a preliminary study. Eur J Radiol. 2018;108:13–20.
32. Hirooka Y. Ultrasonographic diagnosis of pancreatic diseases: this is all you need. J Med Ultrason. 2020;47:489.
33. Hirooka Y, Kuwahara T, Irisawa A, et al. JSUM ultrasound elastography practice guidelines: pancreas. J Med Ultrason. 2015;42:151–74.
34. Suzuki H, Kawashima H, Ohno E, et al. What is the role of measuring shear wave dispersion using shear wave elastography in pancreatic parenchyma? J Med Ultrason. 2020;47:575–81.
35. Ohno E, Hirooka Y, Kawashima H, et al. Feasibility and usefulness of endoscopic ultrasonography-guided shear-wave measurement for assessment of autoimmune pancreatitis activity: a prospective exploratory study. J Med Ultrason. 2019;46:425–33.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.